Lu AF82422

DRUG3 trials

Sponsors

H. Lundbeck A/S

Conditions

HealthyHealthy ParticipantsMultiple System AtrophyParkinson Disease

Phase 1

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

CompletedNCT03611569

H. Lundbeck A/SHealthy, Parkinson Disease

Start: 2018-07-25End: 2021-07-26Updated: 2021-10-12

A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults

CompletedNCT06258720

H. Lundbeck A/SHealthy Participants

Start: 2024-03-18End: 2024-09-03Updated: 2024-11-12

Phase 2

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Active, not recruitingNCT05104476

H. Lundbeck A/SMultiple System Atrophy

Start: 2021-11-16End: 2028-03-07Updated: 2026-04-13

Related Papers

Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422

Movement Disorders2024-03-1732 citations